TransMedics Group is trading 7.9% down at $74.38 after its second-quarter report showed strong revenue growth but weaker-than-expected profitability.
- Revenue of $189.9M beat estimates and the company raised the low end of its 2026 sales guidance.
- EPS of $0.41 missed the $0.50 consensus as operating expenses jumped 49%, pressuring margins.
- Pre-market trading suggests investors are focusing on the earnings miss and cost escalation.